Results are plotted to visualizethem as easily as possible and are sent to each laboratory.Depending on the degree of agreement with the assigned value, thelaboratories are scored and receive a report that enables them to re-view how well they have performed in the test. The results are confi-dential to the laboratory and the organizer, but clients of thelaboratory and the accreditation body may request the test results.Typically, calibration standards are not sent with the sample, and theanalytical methods are not mandated. However, laboratories are ad-vised to report the method because this may be used to obtain infor-mation if the method itself is a source of the deviation from the trueresults.ADVANTAGES FOR LABORATORIESParticipating in proficiency testing schemes can be quite expensive;but the advantages for a laboratory are quite numerous:>> External and independent assessment of data quality for spe-cific tests.>> A means of demonstrating the data quality to customers, ac-creditation bodies, and regulatory agencies.>> A motivation to improve analytical quality.>> Information on the performance characteristics of analyticalmethods and the quality of reference materials.>> A laboratory experiencing difficulty with a particular analysiscan often seek advice from the scheme organizer to improveits processes.>> Investigations can result in improved methods being introducedand, therefore, produce more accurate data.>> Compliance with accreditation standards.REFERENCES[1] ISO/IEC 17043 (2010) Conformity assessment - general requirements forproficiency testing, International Organization for Standardization, Geneva [2] M Reichenba"cher, J.W. Einax: Challenges in Analytical Quality Assurance, Springer-Verlag Berlin Heidelberg 2011, (ISBN 978-3-642-16594-8 e-ISBN 978-3-642-16595-5)[3] H.Ludwig, Validation and qualification in analytical laboratories, 2nd ed. (2007)Informa Healthcare USA, Inc., New York (ISBN-13: 978-0-8493-8267-3)[4] ISO. Proficiency Testing by Interlaboratory Comparisons - Part 1: Developmentand Operation of Proficiency Testing Schemes. Geneva Switzerland. 1997. Guide43-1. [5] ISO IEC: Proficiency Testing by Interlaboratory Comparisons - Part 2: Selectionand Use of Proficiency Testing Schemes by Laboratory Accreditation Bodies.Geneva Switzerland. 1997. Guide 43-2. [6] Thompson M., Ellison S. and Wood R., International harmonized protocol forproficiency testing of chemical analytical laboratories, Pure Appl. Chem 2006., 78(1):145-196 at http://www.iupac.org/publications/pac/2006/pdf/7801x0145.pdf. [7] EDQM Instruction IS7/06, Rev 02 (31/01/2011) Management of ProficiencyTesting Scheme (PTS) UPRAVUVANjE SO TESTOVITE \ZA MEGjULABORATORISKA SPOREDBA J. Atsevska, L. Ugrinova, K. Brezovska, A. PotsevaPanovska, J. Tonikj Ribarska, S. TrajkovikjJolevska, A. DimitrovskaTsentar za ispituvanje i kontrola na lekovi, Farmatsevtskifakultet, Univerzitet ,,Sv. Kiril i Metodij", Skopje,R.Makedonija VOVEDVo vovedniot del na ISO/IEC 17043 [1] e tsitirano:"Megjulaboratoriskite sporedbi voobichaeno, se nameneti za:>> Evaluatsija na performansite na laboratoriite zaspetsifichni ispituvanja ili merenja, kako i sledenje nakontinuiranata kompetentnost na laboratoriite;>> Identifikatsija na laboratoriskite problemi iotpochnuvanje na merki za podobruvanje, shto na primer, mozheda se povrzani so: nesooodvetna protsedura za ispituvanjeili merenje, efektivnosta na obukata na personalot isproveduvanjeto na nadzorot, ili kalibratsija na opremata;>> Obezbeduvanje na dopolnitelna doverba na korisnitsite nauslugite na laboratorijata;>> (...)".Testovite za megjulaboratoriska sporedba prvenstveno se spro ve -du vaat poradi edna od trite prichini [2]: validatsija na metodot(stu dii za protsenka na performansite na metodot), validatsija nareferentni materijali (studii za sertifitsiranje na referentenmaterijal) ili protsenka na performansite na laboratorijata(studii za protsenka na veshtini).Protsenkata na laboratoriskite veshtini za sproveduvanje naispituvanjata ima dve kluchni tseli: obezbeduvanje na redovni,objektivni i nezavisni protsenki na verodostojnosta (koja vkluchuvatochnost i pretsiznost) na analitichkite rezultati za rutinskiprimerotsi, kako i promotsija na podobruvanje na kvalitetot naanalitichkite podatotsi.Uspeshnoto uchestvo vo studiite za protsenka na veshtina dokazhuvadeka vospostaveniot sistem za kvalitet funktsionira dobro [3]. Akreditatsionite i sertifikatsionite tela shto vrshat protsenka natekhnichkata kompetentnost na laboratoriite za ispituvanje, voramkite na nivnata otsenka, gi koristat rezultatite dobieni odstudiite za protsenka na veshtina [4]. Rezultatite od sprovedenite studii za protsenka na veshtinapretstavuvaat samo eden od mekhanizmite za sozdavanje na doverbakaj korisnitsite na uslugite na laboratorijata. POSTAPKAStudiite za protsenka na veshtina se sproveduvaat spored protokolshto e razvien kako rezultat na sorabotka megju ekspertite odpovekje zemji pod zaednichka organizatsija na ISO, IUPAC i AOAC [5].Vo ramki na edna voobichaena studija za protsenka na veshtina,organizatorot distribuira dobro definiran primerok za ispi -tuvanje do laboratoriite-uchesnichki. Laboratoriite gi ana li zi ra -at primerotsite koristejkji metodi i standardi shto se pri menuvaatza toj primerok i gi isprakjaat rezultatite na orga ni za torot. Sekojrezultat dobien od razlichnite laboratoriii se spo re duva so vi -stin skata vrednost za ispituvanata karakte ri sti ka na pri me rokot.Postojat pet metodi za opredeluvanje na vistinskata vrednost na16Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA oralni prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOispituvanata karakteristika na primerokot [6]:>> Upotreba na teoretskata vrednost potvrdena so studija nafizibilnost.>> Dodavanje na poznata kolichina ili kontsentratsija naanalitite vo osnovniot primerok shto ne sodrzhi nitu edenod ispituvanite analiti.>> Primena na khemiski referentni supstantsii ili bioloshkireferentni preparati od Evropskata farmakopeja iliSvetskata zdravstvena organizatsija.>> Upotreba na konsenzualna vrednost dobiena od strana nagrupa na eksperti ili referentni laboratorii.>> Upotreba na konsenzualna vrednost dobiena vrz osnova narezultatite od uchesnitsite.Za otsenuvanje na rezultatite dobieni od studiite za protsenka naveshtina se primenuva robustna statistika, so tsel pretvoranje nadobienite podatotsite od laboratoriite vo rezultati shto se lesnorazbirlivi i primenlivi. Sekoj rezultat (x) se pretvora vo "Z"vrednost shto ja opishuva pretkhodno definiranata prifatlivavarijabilnost pomegju laboratoriite. Z vrednosti shto se naogjaatpomegju dve standardni devijatsii se smetaat za zadovolitelni (95%od sluchaite). Z vrednosti megju dve i tri standardni devijatsii sesmetaat za somnitelni i se javuvaat kaj 5% od site sluchaite. No,samo onie rezultati nadvor od podrachjeto na tri standardnidevijatsii se smetaat za nezadovolitelni. Rezultatite se pret sta vu -vaat grafichki i se isprakjaat do sekoja laboratorija-uchesnichka.Vo zavisnost od stepenot na sovpagjenje so vistinskata vrednost,laboratoriite dobivaat izveshtaj shto ovozmozhuva protsenka nakvalitetot na sproveduvanje na studijata. Rezultatite se doverliviza laboratorijata i organizatorot, no po potreba mozhe sedostapni i za korisnitsite na uslugite od laboratorijata i zaakreditatsionoto telo. PREDNOSTI ZA LABORATORIIUchestvoto vo studiite za protsenka na veshtina nosi brojniprednosti za laboratorijata:>> Nadvoreshna i nezavisna otsenka na kvalitetot na podatotsiteza spetsifichni metodi.>> Nachin na demonstriranje na kvalitetot na podatotsite odlaboratoriskite ispituvanja na korisnitsite na uslugite,akreditatsionite tela i regulatornite organi.>> Podobruvanje na sistemot za kvalitet.>> Informatsii za karakteristikite na analitichkite metodi ikvalitetot na referentnite materijali.>> Preispituvanjeto mozhe da rezultira so podobruvanje na vo -ve denite metodi, a so toa i tochnosta na dobienite po da to tsi.>> Usoglasenost so standardite za akreditatsija.LITERATURA[1] ISO/IEC 17043 (2010) Conformity assessment - general requirements forproficiency testing, International Organization for Standardization, Geneva [2] M Reichenba"cher, J.W. Einax: Challenges in Analytical Quality Assurance,Springer-Verlag Berlin Heidelberg 2011, (ISBN 978-3-642-16594-8 e-ISBN 978-3-642-16595-5)[3] H.Ludwig, Validation and qualification in analytical laboratories, 2nd ed. (2007)Informa Healthcare USA, Inc., New York (ISBN-13: 978-0-8493-8267-3)[4] ISO. Proficiency Testing by Interlaboratory Comparisons - Part 1 Developmentand Operation of Proficiency Testing Schemes. Geneva Switzerland. 1997. Guide43-1 & Part 2: Selection and Use of Proficiency Testing Schemes by LaboratoryAccreditation Bodies. Geneva Switzerland. 1997. Guide 43-2. [5] Thompson M., Ellison S. and Wood R., International harmonized protocol forproficiency testing of chemical analytical laboratories, Pure Appl. Chem 2006., 78(1):145-196 at http://www.iupac.org/publications/pac/2006/pdf/7801x0145.pdf. [6] EDQM Instruction IS7/06, Rev 02 (31/01/2011) Management of ProficiencyTesting Scheme (PTS) 17Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS oral presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONFARMATsEVTSKI ANALIZI /OBEZBEDUVANjE KVALITET / REGULATIVAposter prezentatsiiPHARMACEUTICAL ANALYSIS /QUALITY ASSURANCE / REGULATORY AFFAIRSposter presentationsPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOAN RP-HPLC STUDY FOR THE PKA DETERMINATION OF RIZATRIPTAN AND ITS IMPURITIESBiljana Otasevic, Mira Zecevic, Zorica Vujic andVesna KunticFaculty of Pharmacy, University of Belgrade, Belgrade, Vojvode Stepe450, SerbiaINTRODUCTIONRizatriptan (N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine), (Fig. 1a) is a recently developed antimigraine drug usedfor the treatment of migraines and severe headaches. It is a selectiveserotonin 5-HT1B/1D receptor agonist who blocks the stimulated se-cretion of neuropeptides from trigeminal nerves and breaks the noci-ceptive cycle of migraine. The degradation products of rizatriptan areL-747.019 (Fig. 1b) formed by N-oxidation in the presence of air and L-783.540 (Fig. 1c) formed in the interaction of the drug with the sweet-ener in the formulation (transferring the methyl group from aspartameto the aliphatic tertiary nitrogen in the rizatriptan molecule).OBJECTIVESThe goal of this investigation was to determine the dissociation con-stants (pKa) of rizatriptan and its impurities by the HPLC assay. pKa ofrizatriptan had been already investigated by classical methods likepotentiometry and UV-Vis spectroscopy, but there is no literature datafor pKa of its impurities (1,2).EXPERIMENTALThe standard substances of rizatriptan benzoate, L-747.019 and L-783.540, were obtained from Merck. Chromatographic analyses wereperformed on an HP 1200 (Agilent, Palo Alto, CA, USA) chromatographic system equipped withon-line degasser, binary pump, column oven and photo diode array de-tector. Sample injection was made through Rheodyne injector valvewith a 20 lL sample loop. The method used C18 XTerra (5 mm, 150 mmx3.9 mm) column (Waters, MA, USA). After being loaded onto the col-umn, the samples eluted at a temperature of 20degC at a flow rate of1.0 mL min-1 with the mobile phase consisting of a mixture of 1% TEAand methanol (10:90 v/v) while pH of the water phase was Fig 1. The structure of rizatriptan and its impuritiesadjusted from 2 to 10 with orthophosphoric acid. The detection wasperformed at 225 nm. Solutions for the determination of dissociationconstants were prepared in water in conacentration of 5mgmL-1.RESULTS AND DISCUSSIONPlots of the retention factor versus pH are presented in Fig. 2 for riza-triptan a) and its impurities b) and c). Typical sigmoidal curves wereobtained for mobile phase of 10% MeOH. The observed retention fac-tors versus pH of the mobile phases were fitted to the equation (Boltz-man sigmoid Y = bottom + (top) bottom)/[1 + exp(V50) X)/slope]), usinga non-linear least square program (Origin 7.0) (3). Computer generatedplots k versus pH were obtained and the pH value at the inflectionpoint (V50) was taken as valuable index of apparent pKa. Using po-likratic method (plot of apparent pKa versus percentage of methanol)the real pKa values were obtained: for rizatriptan: pKa=9.477, for im-purity L-747.019: pKa=6.298 and for impurity L-783.540 pKa= 6.157.CONCLUSIONThe proposed method enable accurate determination of pKa values,since the obtained value for rizatriptan is in agreement with literaturedata.20Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA poster prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOFig. 2. Plots of the retention factor of risatriptan and its impuritiesversus pHREFERENCES1.